Responses from individual targets are grouped according to target class into virtual assays panels that mirror those widely used in in-vitro screening assays. For each compound they provide instant information concerning possible area of application, off-target prediction, as well as potential safety concerns.
Protein kinases
Kinase binding assays play a crucial role in drug design, particularly in the development of targeted therapies. Our virtual kinase binding assay provides for rapid selection of putative protein kinase binders, as well as for initial selectivity profiling. It comprises 318 unique targets (with 302 human proteins), including 227 serine/threonine kinases and 74 tyrosine kinases.
| Assay type | Protein genes |
| Serine/threonine kinases | AAK1, ACVR1, ACVR1B, ACVRL1, AKT1, AKT2, AKT3, ARAF, ATR, AURKA, AURKB, AURKC, BCR, BMP2K, BMPR1A, BRAF, BRSK1, CAMK1, CAMK1D, CAMK2B, CAMK2D, CAMK2G, CAMKK2, CDC42BPA, CDC7, CDK1, CDK12, CDK13, CDK19, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDPK1, CHEK1, CHEK2, CHUK, CSNK1A1, CSNK1D, CSNK1E, CSNK1G1, CSNK1G2, CSNK1G3, CSNK2A1, CSNK2A2, DAPK3, DCLK1, DYRK1A, EEF2K, EIF2AK1, EIF2AK3, EIF2AK4, GAK, GRK2, GRK5, GSK3-BETA, GSK3A, GSK3B, HASPIN, HIPK2, HIPK4, IKBKB, IKBKE, ILK, IRAK1, IRAK4, LATS1, LIMK1, LIMK2, LRRK2, MAP3K11, MAP3K12, MAP3K14, MAP3K20, MAP3K5, MAP3K7, MAP3K8, MAP3K9, MAP4K1, MAP4K2, MAP4K3, MAP4K4, MAP4K5, MAPK1, MAPK10, MAPK11, MAPK12, MAPK13, MAPK14, MAPK3, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK5, MARK2, MARK3, MELK, MINK1, MKNK1, MKNK2, MTOR, NEK2, NEK4, NUAK1, PAK1, PAK4, PDK1, PDK2, PDK3, PDK4, PDPK1, PHKG2, PIM1, PIM2, PIM3, PKMYT1, PKN1, PKN2, PKNB, PLK2, PLK3, PLK4, PRKAA1, PRKAA2, PRKACA, PRKACB, PRKACG, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCH, PRKCI, PRKCQ, PRKCZ, PRKD1, PRKD2, PRKD3, PRKG1, PRKG2, PRKX, RAF1, RIPK1, RIPK2, RIPK3, ROCK1, ROCK2, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA5, RPS6KA6, RPS6KB1, SGK1, SGK2, SIK2, SLK, SRPK1, STK10, STK16, STK17A, STK17B, STK3, STK4, TAOK1, TAOK3, TBK1, TGFBR1, TGFBR2, TNIK, TNNI3K, TSSK1B, ULK1 |
| Tyrosine kinases | ABL1, ABL2, ALK, AXL, BLK, BMX, BTK, CSK, DDR1, DDR2, EGFR, EPHA2, EPHA4, EPHB4, ERBB2, ERBB4, FER, FES, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1, FLT3, FLT4, FRK, FYN, HCK, IGF1R, INSR, ITK, JAK1, JAK2, JAK3, KDR, KIT, LCK, LTK, LYN, MERTK, MET, MST1R, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PTK2, PTK2B, PTK6, RET, ROS1, SRC, SRMS, SYK, TEC, TEK, TNK1, TNK2, TXK, TYK2, TYRO3, WEE1, YES1, ZAP70 |
GPCRs
G-Protein Coupled Receptors (GPCRs) are a key group of protein targets owing to their abundance, diversity, clinical relevance, and well-established druggability. At the some time, GPCRs pose unique challenges for in vitro screening approaches due to their integral membrane protein nature. Our virtual GPCR binding assay provides quick and easily accessible initial assessment of small molecule affinity and selectivity across a broad spectrum of receptors. The panel includes 230 unique GPCR targets (with 154 human proteins).
| Assay type | Protein genes |
| GPCRs | ACKR3, ADORA1, ADORA2A, ADORA2B, ADORA3, ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, AGTR1, AGTR1B, AGTR2, APLNR, AVPR1A, AVPR1B, AVPR2, BDKRB1, BDKRB2, C3AR1, C5AR1, CALCR, CALCRL, CCKAR, CCKBR, CCR1, CCR2, CCR3, CCR4, CCR5, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CNR1, CNR2, CXCR1, CXCR2, CXCR3, CXCR4, CYSLTR1, CYSLTR2, DRD1, DRD2, DRD3, DRD4, DRD5, EDNRA, EDNRB, F2R, F2RL1, FFAR1, FFAR2, FFAR4, FPR1, FPR2, FPRL2, GALR2, GCGR, GHSR, GNRHR, GPBAR1, GPM3, GPR35, GPR6, GPR84, GRM1, GRM2, GRM3, GRM4, GRM5, GRM7, HCAR2, HCRTR1, HCRTR2, HRH1, HRH2, HRH3, HRH4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7, LTB4R, MC1R, MC3R, MC4R, MC5R, MCHR1, MTNR1A, NMUR1, NMUR2, NPBWR1, NPY1R, NPY2R, NTSR1, NTSR2, OPRD1, OPRK1, OPRL1, OPRM1, OXTR, P2RY1, P2RY12, P2RY14, P2RY2, P2RY4, P2RY6, PTAFR, PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, RXFP1, RXFP2, S1PR1, S1PR3, S1PR4, S1PR5, TAAR1, TACR1, TACR2, TACR3, TBXA2R, TRHR, TSHR |
Ion channels
Ion channel binders constitute important drug groups across a number of diverse therapeutic areas. At the same time, unintended modulation of ion channel activity is a frequent cause of safety issues. Our in silico channel binding assay allows efficient profiling of drug candidates, as well as fast screening for undesired off target activity, including the human Ether-à-go-go-Related Gene (hERG) ion channel, a primary focus for safety testing. The panel includes 137 ion channels (with 66 human targets).
| Assay type | Protein genes |
| Ion channels | CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1S, CFTR, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, HTR3A, KCNA3, KCNA5, KCNH2, KCNJ11, KCNJ8, KCNQ2, MCOLN3, NOX1, P2RX3, P2RX4, P2RX7, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN9A, TRPA1, TRPM2, TRPM8, TRPV1, TRPV2, TRPV4, VPR |
Cytochrome P450
Cytochrome P450 (CYP450) are ubiquitous enzymes responsible for the biotransformation of a wide range of compounds. Accordingly, screening of drug candidates’ interaction with CYP450 enzymes is vital for the assessment of their metabolism, bioavailability, and potential toxicity. Our virtual CYP450 assay covers 12 enzymes, including 11 human proteins.
| Assay type | Protein genes |
| Cytochrome P450 | CYP17A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP51 |
Nuclear receptors
Nuclear receptors regulate gene expression in response to specific molecular ligands. They are important drug targets in a number of diseases, including hormone-related cancers, metabolic disorders, and autoimmune diseases. The nuclear receptor panel includes 34 unique proteins, with 31 human targets.
| Assay type | Protein genes |
| Nuclear receptors | AR, ESR1, ESR2, ESRRA, ESRRG, HNF4A, HPRT1, NR1I2, NR3C1, NR3C2, PGR, PPARA, PPARD, PPARG, PPIA, RARA, RARB, RARG, RORB, RORC, RXRA, RXRB, RXRG, THRA, THRB, VDR |
Enzymes
Enzymes are among the most important and widely targeted proteins in drug discovery and development due to their central roles in various biochemical pathways and cellular processes. Our panel of virtual binding assays offers possibility for high throughput profiling of enzyme-targetting drug candidates across 597 diverse enzymes, including the most relevant enzyme classes.
| Assay type | Protein genes |
| Oxidoreductases | AKR1B1, AKR1C3, ALOX5, AOC3, CYP17A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP51, DAO, DHFR, DHOD, DHODH, EGLN1, FABI, FOLA, HMGCR, HPGD, HSD11B1, HSD11B2, HSD17B1, IDO1, IMPDH2, INHA, KDM1A, KDM4A, KDM4C, KDM4E, KDM5A, LDHA, LDHB, MAOA, MAOB, NOS1, NOS2, NOS3, NOX1, NQO1, NQO2, PHGDH, PPO2, PTGS1, PTGS2, SRD5A2, TDO2, TXNRD1, TYR |
| Transferases (in addition to protein kinases) | CARM1, DNMT1, DOT1L, EHMT1, EHMT2, EP300, EZH2, FASN, FDFT1, FDPS, FNTA, FNTB, GGPS1, GSTP1, HPRT1, ICMT, KAT2B, KMT2A, MAT2A, MDM2, NAMPT, NCOA1, NMT1, NNMT, NSD2, PARP1, PARP2, PGGT1B, PNMT, PNP, PRMT1, PRMT5, PRMT6, PYGL, QPCT, SIRT1, SIRT2, SIRT3, SIRT5, SMYD2, SOAT1, TGM2, THYA, TNKS, TNKS2, TYMS, UBE2N, XIAP |
| Hydrolases | ABHD6, ACE, ACHE, ACP1, ADA, ADAM17, ADAMTS5, AHCY, ALPG, ALPI, AMPC, ANPEP, APEX1, APOBEC3A, APOBEC3F, APOBEC3G, ASAH1, ATAD2, BACE1, BACE2, BCHE, BLA, BLA(TEM-2), BLM, C1S, CAPN1, CAPN2, CASP1, CASP3, CASP7, CASP8, CD38, CDC25B, CES2, CMA1, COLA, CPB2, CTSB, CTSD, CTSG, CTSK, CTSL, CTSS, DCTPP1, DEF, DNAB, DPEP1, DPP4, DPP7, DPP8, DPP9, DUSP3, DUSP6, ECE1, ELANE, ENPP2, ERAP1, ERAP2, F10, F11, F12, F2, F7, F9, FAAH, FAP, FBP1, FEN1, GAA, GALC, GBA1, GBA2, GLS, HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HSP90AA1, KLK1, KLK5, KLK7, KLKB1, KRAS, LEF, LNPEP, LPXC, LTA4H, M18AAP, MALT1, MAP, METAP1, METAP2, MGLL, MME, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP7, MMP8, MMP9, NA, NAAA, NLRP3, NOTUM, NPR, NT5E, PA, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE7A, PDE9A, PLA2G1B, PLA2G2A, PLAT, PLAU, PLG, PMII, PNLIP, PPP1CA, PREP, PRSS1, PRSS2, PRSS3, PSEN1, PSEN2, PSMB5, PSMB8, PSMB9, PTPN1, PTPN11, PTPN2, PTPN22, PTPN5, PTPN7, PTPRC, RECQL, REN, SENP6, SENP7, SENP8, SMPD1, STS, STX1, TDP1, TDP2, TMPRSS15, TMPRSS6, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3E, TUBA4A, USP1, USP19, USP2, USP7, VCP |
| Lyases | CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, GLO1 |
| Isomerases | FKBP1A, FKBP5, GYRA, GYRB, MIF, MPI, P4HB, PIN1, PPIA, PTGES, TBXAS1, TOP1, TOP2A, TOP2B |
Transporters
Transporters play a multifaceted role in drug design by influencing drug absorption, distribution, metabolism, and excretion. Understanding transporter-mediated processes and interactions is crucial for optimising drug efficacy, minimising side effects, and ensuring the safe and effective use of medications. Our in siliico transporter screening assay includes 14 targets.
| Assay type | Protein genes |
| Transporters | ABCB1, ABCG2, SLC1A2, SLC29A1, SLC2A1, SLC5A1, SLC5A2, SLC6A1, SLC6A2, SLC6A3, SLC6A4, SLC6A5, SLC6A9, SLCO1B1 |